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ABSTRACT 
Aim: In this study, we aimed to estimate one- to five-year survival rates in Iranian patients with gastric cancer (GC). In 
addition, we preformed subgroup analyses and meta-regression to explore possible sources of heterogeneity between 
studies. 
 Background: According to literatures, there has been increasing attention to the long-term survival rate in patients with 
GC in Iran. However, results have been inconsistent and remain controversial in overall survival rates.  
Patients and methods: Literature searches were conducted using PubMed, Scopus, and ISI, as well as Magiran, Medlib, 
SID, and Iran Medex databases. Studies were pooled and summary one to five survival rates were calculated. Univariate 
and multivariate regression analyses were used to explore possible sources of heterogeneity among studies. Subgroup 
analyses were also conducted. Analyses were conducted using the STATA statistical software package. 
Results: Final analysis of 29361 patients from 26 eligible studies was performed. The overall survival rate (one to five years) 
in all studies, by meta-analysis of 24, 14, 23, 12 and 22 studies were 52%, 31%, 24%, 22%, and 15%, respectively. Meta-
regression analysis showed an increase in one- and five-year survival rate over the time (Reg Coef = 0.016, p= 0.04) and (Reg 
Coef= 0.021, p= 0.049), respectively. Positive heterogeneity was observed between quality of papers and data sources 
(P<0.001).  
Conclusion: More than half of GC deaths happened in the first year at diagnosis, and another 30% plus they occurred 
during the second year after confirmed diagnosis. Our results admit lower survival rates in Iran, similar to other 
developing countries.   
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Introduction  
  1 Every year, 7 million lives are lost due to 
preventable and treatable cancers (1). Incidence 
rates of cancers could increase substantially in the 
future, with up to 15 million new cases in 2020, 
most of which will be in developing countries (2). 
Among all cancer types, gastric cancer (GC) is one 
of the leading causes of death in recent decades, 
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and its death toll has been steadily increasing in 
Asia and across the globe (3). Environmental 
factors such as obesity and gastroesophageal 
reflux disease are thought to contribute to its 
deadliness (4). At diagnosis, 23% of GC cases are 
localized, 32% are detected in the lymph nodes, 
and 34% are metastatic (5). In localized cases, 
treatment usually involves a combination of 
surgery, radiation, and chemotherapy, 
supplemented with adjuvant therapy (6, 7). 
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Misdiagnosis is the greatest obstacle facing 
treatment of GC in Iran (8-10). In most cases, by 
the time the disease is detected and properly 
diagnosed, surgery is the only viable option. 
Therefore, early detection and screening programs 
are critical to improve prognoses in GC patients 
(11, 12). In the last decade, there are a growing 
number of Iranian studies, which have focused on 
the rate of GC survival. Results of these studies 
indicate that survival rates in Iran are consistent 
with those in other developing countries, but lower 
than those in developed countries (13).  
It is difficult to conduct population-based cancer 
studies in Iran, due to incomplete hospital records, 
careless registration processes, insufficient 
training, haphazard patient follow-up policies, and 
a lack of regional and provincial cancer centers. 
Inconsistent GC survival rates are also a prevalent 
feature in Iranian medicine, the lowest and highest 
of which were 81% (14) and 21% (15), 
respectively, for one year, and 31% (16) and 5.4% 
(17), respectively, for five years.  
According to our research, no recent systematic 
review has focused on GC survival in Iran. The 
present study intends to contribute to the extant 
literature by providing a systematic review and 
meta-analysis of one- and five-year survival rates 
in Iranian GC patients, and performing subgroup 
analyses and meta-regression to explore possible 
sources of heterogeneity among included studies.  
 
Methods 
Through an electronic and manual search, 102 
papers were identified (Table1). After exclusion of 
reviews and duplicate articles, as well as title 
screen, 43 separate publications remained for 
further appraisal. Remained articles, subsequent to 
abstract and full text review we removed 17 
publications according to exclusion criteria and in 
final data set consisted of 26 publications (Figure 
1). Interpretation results of table 2 shows attention 
to survival rate in patients with GC in Iran is 
increasing as if (64.4%) of final articles were 
published in 2011 onwards. Hospital records were 
the primary data source for the greater part of 
studies (61.5%). The pooled participants in the 
study were 29361 patients with GC (Table1).  
Twenty-four eligible papers including 28949 
patients were included in meta-analysis to estimate 
of one-year survival rate. The overall one year 
survival rate in patients with GC in Iran was 0.52 
(95% CI: 0.52 to 0.53). A significant 
heterogeneity among these studies was observed 
(heterogeneity statistic= 379.79, P<.001, I2= 
98.5%, 95% CI 97.4–99.8) (Figure 2).   
For Meta-analysis of five-year survival rate 
twenty-two publications with 28268 patients were 
considered. The overall five year survival rate in 
patients with GC in Iran was 0.15 (95% CI: 0.15 
to 0.16).  
 
Figure 1. Flow diagram shows different steps 
involved in searching for relevant publications 
(2005–2015). 
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Table 1.Feature and characteristic studies included in study 
Ref. 
No. 
First Author 
(Year of Pub)  
Years of flow  
Sitting 
No. of 
Patients 
Data source Analysis Survival Rate (%) Quality* 
1-
Year 
2-
Year 
3-
Year 
4-
Year 
5-
Year 
(19) Biglarian A 
2011 
2002-2007, 
Tehran 
436 Hospital records Cox proportional hazards 78 53 41 32 17 High 
(20) Mehrabian AA 
2010 
2001-2006, 
National 
19537 Iran Cancer 
Registration 
Center 
Life time table 49 29 23 23 15 High 
(16) Soroush A 
2013 
2008-2010,  98 Hospital records Kaplan–Meier method and Cox 
proportional hazard models 
60    31 High 
(21) Zare A 
2013 
1995-1999,  
National 
330 Iran Cancer Institute Cox proportional hazards model 66 42 31 26 21 High 
(22) Baghestani AR 
2009 
2003-2008, 
Tehran 
178 Hospital records Bayesian Weibull and 
Exponential models 
80 52 35   High 
(23) Moghimi-
Dehkordi B 
2008 
2001-2006, 
Tehran 
746 Cancer Registry 
Center 
life-table method and Wilcoxon 
(Gehan) test 
73 50 40 33 29 High 
(24) Samadi F 
2007 
2000-2004, 
Ardabil 
279 Hospital records Kaplan–Meier method and Cox 
proportional hazard models 
41    8 High 
(25) Noorkojuri H 
2013 
2003-2008, 
Tehean 
216 Tehran Cancer 
Registry 
Cox proportional hazards and 
smoothing methods 
80 56 40 35 30 High 
(26) Yazdani-Charati 
J 
2014 
2007-2010, 
Sari 
190 Hospital records Kaplan-Meier 
method 
45 26 8   High 
(27) Ghadimi Gh 
2011 
1990-199, 
Babol 
484 Cancer Registration 
Center 
 Weibull, Log-normal, and the 
Log-logistic model 
24  16  15 High 
(28) Maroufizadeh S 
2011 
2003-1008, 
Tehean 
213 Cancer Registration 
Center 
Cox and Additive hazards models 79  35  14 High 
(15) Bashash M, 
2011 
2004, 
Ardabil 
261 population-based 
cancer registries  
Life-tables 21     High 
(29) Movahedi M, 
2009 
2001-2005, 
National 
3189 national cancer 
registry  
Kaplan-Meier 
method 
48 27 19 16 13 High 
(17) Veisani Y, 
2013 
2006-2011, 
Sanandaj 
239 Hospital records Kaplan-Meier 
method 
41 17 13 10 6 High 
(30) Atoof F, 
2010 
1995-2004, 
Tehran 
330 Hospital records Kaplan-Meier and Weibull Cure  
Models 
  32  20 Medium 
(31) Roshanaei Gh, 
2012 
2003 – 2007, 
Tehran 
400 Hospital records Cox proportional hazards 74 54 31 26 23 Medium 
(32) Moghimi-
Dehkordi B, 
2007 
2001-2005, 
Tehran 
442 Cancer Registration 
Center 
Kaplan–Meier and Cox 
proportional hazard models 
54 30 24 18 16 Medium 
(33) Barfei F, 
2014 
2007-2008, 
Tehran 
99 Hospital records Kaplan–Meier and Cox 
proportional hazard models 
59  40  18 Low 
(34) Kashani H, 
2011 
1995-1999, 
Tehran 
330 Hospital records Kaplan–Meier and Cox 
proportional hazard models 
62 41 31 24 20 Medium 
(35) Baeradeh NA, 
2015 
2006-2010, 
Yazd 
136 Hospital records Kaplan–Meier and Cox 
proportional hazard models 
61 45 31 26 25 Medium 
(36) Zeraati H, 
2005 
1995-1999, 
Tehran 
129 Hospital records A non-homogenous semi-
Markovian stochastic process 
67  31  19 Medium 
(37) Ghorbani S, 
2013 
2007-2012, 
Sari 
430 Cancer Registration 
Center 
Kaplan - Meier and 
univariate analysis 
64 44 34 28 19 Medium 
(14) Roshanaei Gh, 
2010 
2003-2007, 
Tehran 
262 Hospital records Kaplan–Meier and Cox 
proportional hazard models 
81  45  30 Low 
(38) Roshanaei Gh, 
2011 
2003-2007, 
Tehran 
93 Hospital records Kaplan–Meier models 42  19  13 Medium 
(39) Larizadeh 
MH,2013 
2003-2011-
Kerman 
82 Hospital records Kaplan-Meier methods   53  22 Low 
(40) Gohari MR, 
2014 
2002-2007, 
Tehran 
232 Hospital records Kaplan-Meier methods 77  26   Low 
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A significant heterogeneity among these 
studies was observed (heterogeneity statistic= 
472.23, P<0.001, I 2 = 91.8% (95% CI: 90.1–93.5) 
(Fig. 3).  Subgroup analysis was preformed to 
explore possible sources of heterogeneity among 
studies. Results of subgroup analysis showed a 
positive heterogeneity between quality of papers 
and data sources (P< 0.001). Table 2 presented 
these results; one- to five-year survival rate in 
publication with good quality is lower than articles 
with medium and low quality, respectively. Also 
one- to five-year survival rate in studies with 
cancer registry center data source is lower than 
hospital records. Results of meta-regression 
showed an association between publication year 
and one year survival rate, as well as five-year 
survival rate. Thus, year of publication is one of 
the main causes of variability in results of one- to 
five-year survival rate (Reg Coef= 0.016, p= 0.04) 
and (Reg Coef= 0.021, p= 0.049), respectively 
(Fig. 4). According to results, an increasing rate of 
survival was observed across the study period. 
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Figure 3. Meta-analysis of the five year survival rate by different data source (Hospital Records and Cancer 
Registry Centers). 
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Figure 2. Meta-analysis of the one survival rate by data source (Hospital Records and Cancer Rejestry Centers). 
(Squares represent effect estimates of individual studies with their 95% confidence intervals of one survival rate 
with size of squares proportional to the weight assigned to the study in the meta-analysis. The diamond represents 
the overall one survival rate and 95% confidence interval of the random-effects meta-analysis). 
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Also, we examined sample size as another 
explanatory factor to variability in results, which 
showed sample size was another reason for this 
inconsistency in results (Reg Coef= 0.00033, p= 
0.027). Studies with a large sample size had a 
lower survival rate compared to studies with small 
sample size.  
 
Results 
Using electronic searches, 102 papers were 
identified. After exclusion of reviews and duplicate 
articles and title screen, 43 separate publications 
remained for further appraisal. Remained articles, 
subsequent to abstract and full text review, we 
removed 17 publications according to the exclusion 
criteria and in the final data set consisted of 26 
publications (Fig. 1). Interpretation results of table 
2 shows attention to survival rate in patients with 
GC in Iran is increasing as if (64.4%) of final 
articles were published in 2011onwards. Primary 
data source for the greater part of studies (61.5) was 
hospital records.  
The pooled participants in study were 29361 
patients with GC (Table 1).  
Twenty-four eligible papers, including 28949 
patients were included in meta-analysis to estimate 
one-year survival rate. The overall one-year 
survival rate in patients with GC in Iran was 0.52 
(95% CI: 0.52 to 0.53). There was a significant 
heterogeneity among these studies (heterogeneity 
statistic = 379.79, P<0.001, I 2 = 98.5%, 95% CI 
97.4–99.8) (Fig. 2).   
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Figure 4. Meta-regression plots of change in one and 
five survival rate according to changes in continuous 
study moderator’s year 
 
For Meta-analysis of five-year survival rate, we 
considered twenty-two publications with 28268 
patients. The overall five year survival rate in 
patients with GC in Iran was 0.15 (95% CI, 0.15 
to 0.16). A significant heterogeneity among these 
studies was observed (heterogeneity statistic= 
472.23, P<0.001, I 2= 91.8% (95% CI: 90.1–93.5) 
(Fig. 3).  Subgroup analysis was performed to 
Table 2. Subcategories analysis of one to five survival rates by quality and data source 
Subcategories Survival Rate%  (95% CI) Heterogeneity 
1-Year 2-Year 3-Year 4-Year 5-Year I2 (%) P value 
Quality High 51(50-51) 30(29-30) 23(22-23) 22(22-23) 15(14-15) 98.8 <0.0001 
Medium 63(61-65) 42(39-44) 29(28-31) 24(22-26) 19(18-21) 89.6 <0.0001 
Low 77(73-80) - 38(34-41) 22(13-31) 26(21-30) 87.5 <0.0001 
Data Source Hospital records 67(65-68) 41(38-43) 27(26-29) 22(20-24) 16(14-17) 96.7 <0.0001 
Cancer registry center 50(49-51) 30(29-30) 23(23-24) 22(22-23) 15(15-16) 97.7 <0.0001 
Overall survival rate  52(52-53) 31(30-31) 24(23-24) 22(22-23) 15(15-16) 95.6 <0.0001 
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explore possible sources of heterogeneity among 
studies. Results of subgroup analysis showed a 
positive heterogeneity between quality of papers 
and data sources (P<0.001). Table 2 presented 
these results; one- to five-year survival rate in 
publication with good quality is lower than articles 
with medium and low quality, respectively. Also, 
one- to five- year survival rate in studies with 
cancer registry center data source is lower than 
hospital records.  Results of meta-regression 
showed an association between publication year 
and one-year survival rate, as well as five-year 
survival rate. Thus, year of publication is a cause 
of variability in results of one and five year 
survival rate (Reg Coef= 0.016, p= 0.04) and (Reg 
Coef= 0.021, p= 0.049), respectively (Fig. 4). 
According to results, an increasing survival rate 
across the study period was observed. Also, we 
examined the sample size as other explanatory 
factor to variability in results and results showed 
sample size was another reason for this 
inconsistency in results (Reg Coef= 0.00033, p= 
0.027). Studies with larger sample size had a 
lower survival rate. 
 
Discussion 
In the present meta-analysis, we employed a 
large sample size to generate a reliable estimation 
of GC patient survival rates. We found a 
significant heterogeneity in our results, sources of 
which we explored using meta-regression and 
stratified subgroup analysis according to 
characteristics of the included studies. Our results 
showed that sample size and publication year were 
significant contributing factors to heterogeneity, 
where larger sample size and later year of 
publication were associated with a lower recorded 
rate of survival. In the present study, heterogeneity 
might result from different characteristics of 
patients, differing stages of disease progression, 
adjuvant treatment, duration of patient follow-up, 
or histological type. Due to limited resources in 
previous studies, we were unable to specify the 
role of these features that might contribute to 
disparate survival rates. 
Ultimately, 26 studies were incorporated into 
our meta-analysis. Estimation of overall survival 
rate, and the one- through five-year rates of 24, 14, 
23, 12, and 22 were 52%, 31%, 24%, 22%, and 
15%, respectively. These numbers indicate that 
more than half of GC deaths occurred within the 
first year following diagnosis, and another 30% 
took place during the second year. It is the greatest 
difficulty about patients with GC in Iran versus 
worthwhile clinical finding to correct rational 
strategies to address these problems. Various 
histological and demographic factors such as age, 
gender, surgery and treatment type, cancer site, 
grade of tumor, as well as metastasis have been 
found to impact the rate of GC survival in Iran. An 
investigation into risk factors associated with GC 
may help to reduce the probability of death in 
patients. Other strategies include a comprehensive 
follow-up plan for patients with premature signs 
of the disease, as well as the study and application 
of suitable treatments (5). 
Results of the present study suggest that the 
overall five-year survival rate in Iran (15%) is 
lower than the survival rate in countries such as 
China (29.6%), the United States (37%), 
Switzerland (22%), France (30%), and Japan (40-
60%)(1, 13, 41). We classify possible explanations 
for this inconsistency into three main factors: 
cancer stage at diagnosis, patient characteristics, 
and treatment process. In most studies, late 
diagnosis was related to a lower survival rate, 
while diagnosis at an early stage was determined 
to be the most important predictive factor for 
survival. In terms of patient characteristics, a 
lower survival rate was associated with older and 
socioeconomically disadvantaged patients, as well 
as those who did not respond favorably to the 
treatment. Finally, mixed therapies incorporating 
chemotherapy, radiotherapy, and surgery were 
shown to strongly enhance the rate of survival. 
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As mentioned, a nationwide lack of cancer 
registry centers presents an additional obstacle to 
investigating GC in Iran, and the results of this 
study demonstrate this limitation. Although 64.4% 
of sources were derived from cancer registry data, 
the overall survival rates were lower than the 
results obtained from hospital records. Hospital 
records in developing countries are generally 
limited because data are missing, riddled with 
errors, or not deliberately gathered for the purpose 
of later scrutiny. Additionally, eligible patients for 
the present study were from one distinct hospital 
and could not represent all coverage patients in a 
population. 
The present meta-analysis expanded the 
number of participants to produce reliable and 
generalizable results regarding the GC survival 
rate in Iran. Limitations of this study were 
heterogeneity among 26 included studies, a 
scarcity of abstracts, and the inclusion of only 11 
studies out of 102 gathered due to lack of 
available survival statistics. These limitations 
could impact the findings of this analysis.  
According to our research, more than half of 
GC deaths occurred in the first year after 
diagnosis, and another 30% took place during the 
second year. These findings support previous 
reports that suggest a poor diagnosis is the greatest 
challenge to GC patients in Iran. 
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